yes Ninja chook the revenue stream per drug of $4000 per patient seems low given the average per drug currently to extend life about 4 months is about $50,000 from memory.
(Nice pick up by you on that anomaly )
Maybe they are looking at revenue on a royalty/licensing basis?
HC Wainwright Report, page-15
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)